CDKN2A and neoplasm: According to the Japanese algorithm for secondary finding disclosure in cases of tumor-only analysis (http://sph.med.kyoto-u.ac.jp/gccrc/pdf/k101_kentousiryo_v1.pdf), and with the 46.6% variant allele frequency in mind, the Shizuoka Cancer Center expert panel judged the CDKN2A variant (p.G23C) to be a presumed germline pathogenic variant (PGPV).